H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Disc Medicine (IRON – Research Report) today and set a price target of $118.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Douglas Tsao has given his Buy rating due to a combination of factors that highlight the promising potential of Disc Medicine’s bitopertin. The drug has shown consistent and durable efficacy in reducing PPIX levels, which is crucial for improving sunlight tolerance in EPP patients. The HELIOS study data, which includes patients from previous studies, demonstrated significant PPIX reduction, indicating a potential for long-term clinical benefits.
Furthermore, the early signs of improvement in liver function biomarkers suggest additional advantages for patients, which could enhance the drug’s appeal to clinicians. Disc Medicine’s proactive approach in preparing for the commercial launch of bitopertin by 2026, including comprehensive pre-launch activities and educational campaigns, reinforces the confidence in its market potential. These strategic efforts, combined with the positive clinical data, underpin Tsao’s optimistic outlook and Buy rating for Disc Medicine’s stock.
According to TipRanks, Tsao is a 4-star analyst with an average return of 9.4% and a 40.80% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Arcutis Biotherapeutics, Protagonist Therapeutics, and Argenx Se.
In another report released yesterday, LifeSci Capital also maintained a Buy rating on the stock with a $85.00 price target.